Technology

A Next Generation Immunotherapy Platform

The Natural Killer Cell

The immune system is a tapestry of diverse families of immune cells each with its own distinct role in protecting from infections and diseases. Among these immune cells are the natural killer, or NK, cells as the body’s first line of defense. NK cells have the innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules. In contrast to adaptive immune cells such as T-cells, NK cells are uniquely powerful in that they are always activated to attack diseased cells, without a delay in killing. Our proprietary investigational activated Natural Killer (aNK) platform is based upon Natural Killer cells from a unique cell line, harnessing the power of the innate immune system.

Cellon vs. other immunotherapeutic vaccines

DC Vaccine
Cellon

Natural Killer Cells (NK cells), Natural Killer T cells (NKT cells), helper T cells, Antibodies (Abs) can directly or indirectly kill tumor cells.
Most immunotherapeutic vaccines use only parts of them.
However, Celion activates every type of these effectors and are more powerful.

Pipeline

Cellon currently have five immunotherapeutic vaccines in various stages of development.
Clinical trials for BVAC-C (cervical cancer, head and neck cancer, etc.) and BVAC-B (gastric cancer, breast cancer, lung cancer, etc.) are ongoing,
BVAC-P (prostate cancer) clinical trials are planned to start in the first quarter, BVAC-Neo (individualized tumor antigen) and BVAC-M clinical trial are planned to start in the second quarter of 2019.

NK cells

CANCER BINDING

Administered NK cells migrate to the site of the cancer and bind to unique surface proteins on cancer cells

ATTACHMENT-ACTIVATION

Chimeric Antigen Receptors (CARs) on NK cells attach to unique surface proteins on cancer cells and trigger polarization and migration of cytolytic granules to the cancer cell target. Cytokines are also released in the process to attract and recruit additional immune cells into the area.

DEGRANULATION:

Cytolytic granules discharge perforin and granzyme into synapse between the NK cells and cancer cell. Perforins punch holes in the cancer cell membrane, allowing granzymes to enter and degrade the cancer cells from the inside.

ERADICATION

Destructive enzymes break down the cell membrane and internal machinery, including the nucleus with its genetic code. The cancer cell then swells and ruptures, leaving only debris behind.

NKT cells

ANTIBODY & CANCER BINDING

Monoclonal antibodies bind to unique surface proteins on cancer cells

ATTACHMENT-ACTIVATION

Polarization and migration of cytolytic granules to the cancer cell target is triggered by two independent, but synergistic pathways of a) CD16 receptors on t-haNK® cells attach to monoclonal antibodies previously bound to cancer cells and b) Chimeric Antigen Receptors (CARs), also on t-haNK® cells, attach to unique surface proteins on cancer cells. Cytokines are also released in the process to attract and recruit additional immune cells into the area.

DEGRANULATION

Cytolytic granules discharge perforin and granzyme into synapse between the NK and cancer cell. Perforins punch holes in the cancer cell membrane, allowing granzymes to enter and degrade the cancer cells from the inside.

ERADICATION

Destructive enzymes break down the cell membrane and internal machinery, including the nucleus with its genetic code. The cancer cell then swells and ruptures, leaving only debris behind.

DrHARVARD

Dr HARVARD is a R&D specialized bioventure company started in a laboratory in the college of pharmacy, Harvard University.
We are developing innovative immunotherapeutic vaccines, Cellon, that can overcome the medical and technical limitations of current cancer and/or infectious diseases therapies.
Cellon is a personalized vaccine which uses patient’s own cells.
It is a powerful and efficient immunotherapeutic vaccine that activates all types of immune cells usable in our immune system with minimum adverse effects.
Our goal is to improve the quality of life of patients suffering from intractable diseases.

MISSION

To develop personalized immunotherapeutic vaccines for patients with cancers or infectious diseases
that are hard to treat due to medical & technical limitations.
· To introduce new paradigm for immunotherapeutic
vaccines and improve quality of life of patients treated.

VISION

To improve technology through consistent research and development
· To become a global leading biotech-company.

Slider

Subscribe to stay up to date on the security token revolution.

Email*

We won’t send you spam. Unsubscribe at any time.

A member of the Dr Harvard ecosystem of companies Privacy Policy | Legal Notice 

Natural Killer Cells (NK cells), Natural Killer T cells (NKT cells), helper T cells, Antibodies (Abs) are trademarks or registered trademarks of DrHARVARD.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.